A Tufts Center for the Study of Drug Development analysis finds that deploying Medable’s clinical monitoring AI agent in oncology programs could shorten cancer drug clinical development by about 10 weeks and cut direct operating costs in late-stage trials by as much as $5.6 million. For a multi-use medicine aimed at 50 tumor targets, modeled net profit gains could reach up to $565 million.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.
Unlocking the full article...
Contact us
Questions, corrections, or ideas? Send us a message here. We aim to reply by email within 24 hours.
Thank you. Your message has been sent. We aim to reply by email within 24 hours.Please enter your email address and a message.We could not send your message. Please try again in a little while.